Vor Biopharma Inc. SEC filings VOR
Vor Biopharma Inc. has 462 filings in SEC EDGAR's recent list, going back to Jul 10, 2020. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 30, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 7, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Nov 4, 2026 | Nov 2, 2026 |
| 424B5 | Prospectus supplement | Oct 30, 2026 | — |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 4 | Insider transaction | Oct 5, 2026 | Oct 2, 2026 |
| S-3ASR | Automatic shelf registration | Sep 4, 2026 | — |
| 4 | Insider transaction | Aug 26, 2026 | Aug 24, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 7, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 6, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 30, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 21, 2026 | — |
| 4 | Insider transaction | Jul 21, 2026 | Jul 16, 2026 |
| 3 | Initial insider ownership | Jul 9, 2026 | Jul 7, 2026 |
| 4 | Insider transaction | Jul 9, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 7, 2026 | Jul 6, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 8, 2026 | Jun 8, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| EFFECT | Filing | May 6, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 6, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 6, 2026 | — |
| CORRESP | Letter to the SEC | May 4, 2026 | — |
| UPLOAD | Letter from the SEC | May 1, 2026 | — |
| S-3 | Shelf registration | Apr 27, 2026 | — |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Apr 23, 2026 |
| 4 | Insider transaction | Apr 24, 2026 | Apr 22, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 21, 2026 | — |
| 4 | Insider transaction | Apr 21, 2026 | Apr 17, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 15, 2026 | — |
| 4 | Insider transaction | Apr 15, 2026 | Apr 13, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 10, 2026 | — |
| 4 | Insider transaction | Apr 10, 2026 | Apr 8, 2026 |
| 3 | Initial insider ownership | Apr 9, 2026 | Apr 1, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 8, 2026 | — |
| 4 | Insider transaction | Apr 6, 2026 | Apr 2, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 1, 2026 | — |
| 3 | Initial insider ownership | Apr 1, 2026 | Mar 30, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 1, 2026 | — |
| S-8 | Employee stock plan registration | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 27, 2026 | Mar 26, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 16, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| 424B3 | Prospectus | Feb 5, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 5, 2026 | — |
| EFFECT | Filing | Feb 4, 2026 | — |
| CORRESP | Letter to the SEC | Feb 2, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2026 | — |
| S-3 | Shelf registration | Jan 29, 2026 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 2, 2026 | Dec 31, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | Dec 23, 2025 | — |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 3 | Initial insider ownership | Dec 19, 2025 | Dec 18, 2025 |
| 3 | Initial insider ownership | Dec 19, 2025 | Dec 18, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 19, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 18, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Dec 18, 2025 | Dec 15, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 17, 2025 | — |
| 4 | Insider transaction | Dec 9, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 9, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 9, 2025 | Dec 5, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 9, 2025 | Dec 5, 2025 |
| 424B3 | Prospectus | Dec 1, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 18, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 14, 2025 | — |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Other events
|
Nov 12, 2025 | Nov 10, 2025 |
| 424B5 | Prospectus supplement | Nov 12, 2025 | — |
| 424B5 | Prospectus supplement | Nov 10, 2025 | — |
| S-3/A | Filing | Nov 10, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 7, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 5, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 3, 2025 | Nov 2, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 30, 2025 | — |
| 4 | Insider transaction | Oct 30, 2025 | Oct 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2025 | Oct 28, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 27, 2025 | — |
| 4 | Insider transaction | Oct 27, 2025 | Oct 23, 2025 |
| 4 | Insider transaction | Oct 22, 2025 | Oct 20, 2025 |
| 4 | Insider transaction | Oct 21, 2025 | Oct 17, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 20, 2025 | — |
| 144 | Notice of proposed sale | Oct 20, 2025 | — |
| 144 | Notice of proposed sale | Oct 20, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 17, 2025 | — |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 4 | Insider transaction | Oct 17, 2025 | Oct 15, 2025 |
| 144 | Notice of proposed sale | Oct 17, 2025 | — |
| 144 | Notice of proposed sale | Oct 17, 2025 | — |
| 144 | Notice of proposed sale | Oct 16, 2025 | — |
| 144 | Notice of proposed sale | Oct 16, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 16, 2025 | — |
| 4 | Insider transaction | Oct 15, 2025 | Oct 10, 2025 |
| 144 | Notice of proposed sale | Oct 15, 2025 | — |
| 144 | Notice of proposed sale | Oct 15, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 10, 2025 | — |
| 4 | Insider transaction | Oct 10, 2025 | Oct 8, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 8, 2025 | — |
| 4 | Insider transaction | Oct 8, 2025 | Oct 6, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 6, 2025 | — |
| 4 | Insider transaction | Oct 3, 2025 | Oct 1, 2025 |
| UPLOAD | Letter from the SEC | Sep 30, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 26, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 25, 2025 | — |
| S-8 | Employee stock plan registration | Sep 24, 2025 | — |
| S-3 | Shelf registration | Sep 24, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 23, 2025 | — |
| 4 | Insider transaction | Sep 22, 2025 | Sep 18, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 19, 2025 | — |
| 4 | Insider transaction | Sep 18, 2025 | Sep 16, 2025 |
| 8-K |
Current report
Change to shareholder rights, Other events
|
Sep 17, 2025 | Sep 17, 2025 |
| 4 | Insider transaction | Sep 15, 2025 | Sep 11, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 12, 2025 | — |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| 4 | Insider transaction | Sep 10, 2025 | Sep 8, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 9, 2025 | — |
| 3 | Initial insider ownership | Sep 8, 2025 | Aug 27, 2025 |
| 4 | Insider transaction | Sep 5, 2025 | Sep 3, 2025 |
| 144 | Notice of proposed sale | Sep 3, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 2, 2025 | Sep 2, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 29, 2025 | — |
| 4 | Insider transaction | Aug 29, 2025 | Aug 27, 2025 |
| 4 | Insider transaction | Aug 27, 2025 | Aug 25, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2025 | Aug 25, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Aug 27, 2025 | Aug 25, 2025 |
| 424B5 | Prospectus supplement | Aug 27, 2025 | — |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 144 | Notice of proposed sale | Aug 11, 2025 | — |
| DEF 14A | Proxy statement | Aug 8, 2025 | Aug 25, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 6, 2025 | — |
| 144 | Notice of proposed sale | Aug 4, 2025 | — |
| 4 | Insider transaction | Jul 30, 2025 | Jul 17, 2025 |
| 3 | Initial insider ownership | Jul 30, 2025 | Jul 17, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 29, 2025 | Jul 29, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 22, 2025 | Jul 16, 2025 |
| 4 | Insider transaction | Jul 18, 2025 | Jul 16, 2025 |
| 4 | Insider transaction | Jul 18, 2025 | Jul 16, 2025 |
| 3 | Initial insider ownership | Jul 18, 2025 | Jul 16, 2025 |
| 3 | Initial insider ownership | Jul 18, 2025 | Jul 16, 2025 |
| 144 | Notice of proposed sale | Jul 16, 2025 | — |
| 144 | Notice of proposed sale | Jul 15, 2025 | — |
| 4 | Insider transaction | Jul 10, 2025 | Jul 9, 2025 |
| 3 | Initial insider ownership | Jul 10, 2025 | Jul 9, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 10, 2025 | Jul 9, 2025 |
| 144 | Notice of proposed sale | Jul 10, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 9, 2025 | — |
| 144 | Notice of proposed sale | Jul 2, 2025 | — |
| 144 | Notice of proposed sale | Jul 1, 2025 | — |
| 144 | Notice of proposed sale | Jun 30, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 27, 2025 | — |
| 4 | Insider transaction | Jun 27, 2025 | Jun 26, 2025 |
| 3 | Initial insider ownership | Jun 27, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Jun 26, 2025 | Jun 25, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 4 | Insider transaction | May 23, 2025 | May 22, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 23, 2025 | May 22, 2025 |
| 8-K |
Current report
Officer or director change
|
May 20, 2025 | May 19, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 12, 2025 | — |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
May 8, 2025 | May 5, 2025 |
| 4 | Insider transaction | May 7, 2025 | May 6, 2025 |
| 4 | Insider transaction | May 7, 2025 | May 6, 2025 |
| 4 | Insider transaction | May 2, 2025 | May 1, 2025 |
| 4 | Insider transaction | May 2, 2025 | May 1, 2025 |
| 4 | Insider transaction | May 2, 2025 | May 1, 2025 |
| DEFR14A | Filing | Apr 30, 2025 | — |
| 8-K |
Current report
Listing notice
|
Apr 25, 2025 | Apr 22, 2025 |
| ARS | Annual report to shareholders | Apr 8, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 8, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 22, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 3, 2025 | Mar 31, 2025 |
| EFFECT | Filing | Mar 31, 2025 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VOR (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1817229
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.